Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.

Cancer letters - 28 Aug 2016

Wang Ronghao, Lin Wanying, Lin Changyi, Li Lei, Sun Yin, Chang Chawnshang

Abstract excerpt

Androgen deprivation therapy (ADT) with the newly developed powerful anti-androgen enzalutamide (Enz, also known as MDV3100) has promising therapeutic effects to suppress castration resistant prostate cancer (CRPC) and extending patients' lives an extra 4.8 months. However, most Enz therapy eventually fails with the development of Enz resistance. The detailed mechanisms how CRPC develops Enz resistance remain...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgen Antagonists
Share to Antineoplastic Agents, Hormonal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzamides

Share to Curcumin

Share to Nitriles

Share to Prostatic Neoplasms, Castration-Resistant

Share to Proteolysis

Share to Receptors, Androgen

Source

Identifiers

PMID: 27233475
DOI: 10.1016/j.canlet.2016.05.018

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.PMID 27233475Read ↗

Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancerSemantic proximity Read ↗

Discovery of a Small-Molecule Inhibitor Targeting the Androgen Receptor N-Terminal Domain for Castration-Resistant Prostate CancerSemantic proximity Read ↗

ASC-J9 Suppresses Castration-Resistant Prostate Cancer Growth through Degradation of Full-length and Splice Variant Androgen ReceptorsSemantic proximity Read ↗

An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).Semantic proximity Read ↗

Developing a Novel Enzalutamide-Resistant Prostate Cancer Model via AR F877L Mutation in LNCaP Cells.Semantic proximity Read ↗

Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor.Semantic proximity Read ↗

Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical ApplicationsSemantic proximity Read ↗

Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.Semantic proximity Read ↗

Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).Semantic proximity Read ↗

Identification of genes required for enzalutamide resistance in castration-resistant prostate cancer cells <i>in vitro</i>Semantic proximity Read ↗

Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.Semantic proximity Read ↗

High-Dose-Androgen-Induced Autophagic Cell Death to Suppress the Enzalutamide-Resistant Prostate Cancer Growth Via Altering the circRNA-BCL2/miRNA-198/AMBRA1 SignalingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.